Accelerate to discover

Back to filter

Related topics

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers

Agilent technologies

Nov 8, 2021

This technical overview describes advancements in detector technology, and highlights examples where optimal signal...

Jan 26, 2022

X-ray-virus-inactivation

Precision X-Ray

Oct 20, 2021

Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Precision X-Ray

Oct 18, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Jan 26, 2022

Falling in love with Magnetic resonance

Bruker Biospin

Oct 4, 2021

Magnetic Resonance (MR) is more than just analytical science, it is unique, it is a passion that won’t let you go

Show all topics (10)

Digital measurement for HER2 amplifcation in HER2 equivocal breast cancer diagnosis

Sep 20, 2017

Currently, there are no recommended alternative assays for HER2 cases deemed equivocal by immunohistochemistry and fuorescent in situ hybridization. Digital PCR (ddPCR), a highly accurate method to determine DNA copy number, could be a robust alternative for clinical HER2 diagnostics. HER2 and CEP17 copy numbers were quantifed using two ddPCR platforms (QX200 and RainDrop) in 102 samples of invasive breast cancers. Compared to routine assays, ddPCR gave a sensitivity
and specifcity of 82.8% and 97.3% respectively, with a kappa value of 0.833 (p<0.001). Moreover, the method proved to be robust as the results from two platforms was highly correlated R2=0.91; Concordance rate=97%; κ=0.923, P<0.001). Its performance was further tested on 114 HER2 equivocal cases in an independent validation cohort. 75% (21/28) of cases with HER2 amplifcation and 95% (82/86) of HER2 non-amplifed case were classifed as positive and negative by ddPCR respectively (κ=0.709, P<0.001). Notably, in the HER2 amplifed cases, a lower percentage of HER2 positive cells could be related to the discordant results. Altogether, ddPCR is a robust alternative for clinical HER2 diagnostics. However, intratumoral heterogeneity of HER2 status still pose a challenge for HER2 analysis by ddPCR.

Read more

Scientific paper
Application

Get more info

Regina Fillerová

Field application specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

RainDance Technologies

RainDance company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases.

Related products

Capable of generating more than a billion reactions in a single day, the RainDrop system surpasses all existing technologies and establishes a new performance standard in sensitivity, quantitation and multiplexing.

show detail

A fast, accurate and low-cost NGS target enrichment system that features award-winning instrumentation and pre-validated gene panels, as well as flexible open source options.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey